SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 12/15/2017 10:44:53 PM - Followers: 147 - Board type: Free - Posts Today: 11

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

SureTrader
Interactive Brokers Advertisement
AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#5944  Sticky Note Aurinia is no longer just an LN focused Lunacy aka John Galt 11/02/17 03:34:15 PM
#6209   Living the dream, I’m living the nightmare with biotech_researcher 12/15/17 10:44:53 PM
#6208   Stop giving BR more to bash the stock Hotrodder1 12/15/17 08:27:24 PM
#6207   I think I'm getting a ulcer..... What was LivingTheDream 12/15/17 04:33:15 PM
#6206   Perfect... greggors 12/15/17 04:01:31 PM
#6205   Look at the volume!! Definitely Accumulation!! greggors 12/15/17 02:40:27 PM
#6204   Maybe at the end of day ever since LivingTheDream 12/15/17 02:34:46 PM
#6203   Changed my mind...at this ridiculous low price I’m greggors 12/15/17 01:50:14 PM
#6202   Selling is now accelerating......... down another 11.. biotech_researcher 12/15/17 10:27:18 AM
#6201   Greggors, there is another company that was mentioned biotech_researcher 12/15/17 10:17:28 AM
#6200   I will probably hold on...with nothing else out greggors 12/15/17 10:12:25 AM
#6199   Did you mean capital pains? Lol! Just washing Easymoneyman00 12/15/17 07:45:39 AM
#6198   Bingo greggors!!! I will be selling a large biotech_researcher 12/14/17 06:41:16 PM
#6197   Maybe lower for those looking for write offs greggors 12/14/17 05:55:39 PM
#6196   Who was that poster from the Ariad board biotech_researcher 12/14/17 05:43:40 PM
#6195   I would estimate without any positive guidance from cervelo 12/14/17 05:36:46 PM
#6194   The Nasdaq bio index has been flat for greggors 12/14/17 04:10:23 PM
#6193   Well he better not wait too long, the Maciste 12/14/17 03:16:26 PM
#6192   Greggors, who were you responding to????? biotech_researcher 12/14/17 03:11:35 PM
#6191   Absolutely!! AUPH can be Bought Out any greggors 12/14/17 02:51:57 PM
#6190   Comment on AUPH: Re: biotech_researcher Post# 216014 PLSE. Yes Biotech-research biotech_researcher 12/14/17 11:45:54 AM
#6189   I fear the $3’s.......................... biotech_researcher 12/14/17 11:10:36 AM
#6188   Yet the stock is pounded down day after biotech_researcher 12/14/17 11:09:57 AM
#6187   A BuyOut can happen any time now...just based greggors 12/14/17 10:21:42 AM
#6186   148 sites. https://clinicaltrials.gov/ct2/show/NCT03021499?term=Voclosporin&rank LivingTheDream 12/14/17 10:21:12 AM
#6183   $20 to $30 for BO just considering phase greggors 12/13/17 04:24:09 PM
#6182   Nice bounce I might add... biotech_researcher 12/13/17 01:31:02 PM
#6181   lol..."getting killed". Funny guy BR Lunacy aka John Galt 12/13/17 01:25:37 PM
#6180   AUPH getting killed again, down hard. Motley Fool biotech_researcher 12/13/17 10:29:55 AM
#6179   Well, Motley Fool is certainly a public forum biotech_researcher 12/13/17 09:54:11 AM
#6178   Some people with agenda intentionally not post something Jesspro 12/13/17 09:46:01 AM
#6177   Thanks Jess. That gives me hope.. How did biotech_researcher 12/13/17 08:57:50 AM
#6176   Powerful argument for Aurinia’s future... Jesspro 12/13/17 08:42:45 AM
#6175   Looks like any fund following the NASDAQ biotech biotech_researcher 12/12/17 11:52:57 AM
#6174   Minor correction: NBI is the Nasdaq Biotechnology Index. ScifiSailor 12/11/17 04:39:14 PM
#6173   AUPH added to IBB effective next Monday per SA heldnova 12/11/17 01:27:58 PM
#6172   $20 to $30 BO now...much higher by the greggors 12/11/17 11:31:30 AM
#6171   "Biomarker Predicts Lupus Nephritis Flares" moosedogger 12/08/17 11:48:35 AM
#6170   “I think there is a Buy Out coming...just biotech_researcher 12/08/17 10:22:44 AM
#6169   I think there is a Buy Out coming...just greggors 12/08/17 10:01:42 AM
#6168   139 sites. https://clinicaltrials.gov/ct2/show/NCT03021499?term=Voclosporin&rank LivingTheDream 12/08/17 09:54:48 AM
#6167   That ignore button works wonders! the gipper 12/08/17 08:40:51 AM
#6166   Dry Eye- Imprimis Launches 99-Cent Generic Drug To biotech_researcher 12/08/17 06:09:34 AM
#6165   From Forbes heldnova 12/08/17 03:03:03 AM
#6164   Of course if you waited more than 30 heldnova 12/08/17 02:41:02 AM
#6163   It is my opinion that your loss would heldnova 12/08/17 02:01:05 AM
#6162   That’s smart!! Hotrodder1 12/07/17 12:21:41 PM
#6161   Nothing more than washing shares. rumrunner528 12/07/17 11:39:39 AM
#6160   Nothing more than washing shares. In 31 days Easymoneyman00 12/06/17 08:11:49 PM
#6159   On a serious note, are you still invested Jesspro 12/06/17 07:45:15 PM
#6158   Jess, only cervelo can tell you if it biotech_researcher 12/06/17 07:20:38 PM
PostSubject